Taken together, available data indicate that MYC is a suitable therapeutic target, not only for T-ALL patients with NOTCH1/FBXW7 mutations but also for NOTCH-independent T-ALLs where additional signaling pathways, including PTEN and PI3K/AKT (see below), are deregulated. The gene discussed is FBXW7; the disease is acute lymphoblastic leukemia.